A division of the Translational Addiction Medicine Branch
A joint National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) Laboratory
Section Chief
Contact
Location:
Biomedical Research Center
251 Bayview Boulevard
Suite 200, Room 04A515
Baltimore, MD 21224
Phone: 443-740-2801
Email: lorenzo.leggio@nih.gov
NIAAA Website: https://www.niaaa.nih.gov/section-clinical-psychoneuroendocrinology-and-neuropsychopharmacology-cpn
About the Lab
Dr. Leggio’s CPN laboratory conducts clinical and translational inpatient and outpatient studies to identify possible novel medications for addiction. His group uses a combination of state-of-the-art, innovative bio behavioral and pharmacological procedures performed under well-controlled human laboratory conditions. Imaging brain techniques, such as fMRI and PET, are also employed. Dr. Leggio and his team are particularly interested in the role of the gut-liver-brain axis in alcohol- and drug-seeking behaviors. Specifically, the CPN laboratory is currently investigating the potential role of feeding-related pathways, such as ghrelin, leptin, oxytocin and GLP-1, as possible new neuropharmacological targets for the treatment of alcohol and substance use disorders. Other neuroendocrine pathways are also under investigation, such as the aldosterone / mineralocorticoid receptor pathway. The CPN laboratory has recently expanded its research looking at the role of the gut microbiota in heavy drinkers with a special emphasis on the relationships between alcohol-related seeking behaviors and the microbiota-gut-brain axis. Future research includes work on the effects of bariatric surgery on alcohol-related seeking behaviors. Both preclinical and human approaches are under development to shed light on the possible role of these pathways in alcohol and substance use disorders.
